Servier has entered into a definitive agreement with Kaerus Bioscience to acquire KER-0193, a potential first-in-disease treatment for Fragile X syndrome (FXS), the leading...
A leading US-based Applied Behavior Analysis (ABA) therapy provider, Verbal Beginnings, has partnered with The Clinician, a global healthcare company, to pilot a patient reported...
